Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic Conjunctivitis
Statistical Significance Achieved for Primary Endpoint of Ocular Itching at All Prespecified Timepoints (P
